Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Revance Therapeutics Inc (NASDAQ:RVNC), a biotech company developing a botulinum toxin product, could face a competitive backlash, according to JMP Securities.
The Analyst
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Analyst Donald Ellis downgraded Revance from Market Outperform to Market Perform.
The Thesis
The downgrade of Revance is based on Allergan plc (NYSE:AGN)'s recently released data in Botox responders showing that 80 units of Botox 80 produced a more than 1-point improvement in 24 weeks in 39 percent of study patients, Ellis said in a Monday note. (See his track record here.)
Revance is testing RT002, daxibotulinumtoxinA injection, in a Phase 3 study for Glabellar Lines while also pursuing Phase 2 trials for cervical dystonia and plantar fasciitis.
Revance's RT002 showed similar improvement in about 42 percent of study population, the analyst said.
"AGN's data suggest that the longer duration of activity for RT002 may be partially or primarily due to a 'dose' effect," Ellis said.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Allergan's recent data minimizes the benefit of extended duration claims for RT002 vs. Botox, the analyst said.
The FDA requires a more than or equal to 2-point improvement, and none or mild on wrinkle severity, which both companies have not disclosed, he said.
JMP does not expect the companies to make 24-week claims.
"AGN can educate doctors on longer duration with higher doses at medical conferences, but its reps cannot legally promote longer duration directly to doctors," Ellis said.
The Price Action
Revance was down 8.28 percent at $23.55 at the close Monday, while Allergan was down 2.09 percent at $184.29.
Related Links:
Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts
The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.